Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 8/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.47 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.47 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.47 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.47 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.47 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6086383 | 1.00 | MAPK14 (0.49) | MAPK14CHEK1LRRK2FLT3PSEN1 | |
| SCHEMBL6088086 | 0.90 | LRRK2 (0.60) | MAPK14LRRK2FLT3PSEN1PSEN2 | |
| SCHEMBL6086663 | 0.90 | MAPK14 (0.55) | MAPK14LRRK2FLT3PSEN1PSEN2 | |
| SCHEMBL6086658 | 0.90 | MAPK14 (0.55) | MAPK14LRRK2FLT3PSEN1PSEN2 | |
| SCHEMBL6088078 | 0.90 | LRRK2 (0.60) | MAPK14LRRK2FLT3PSEN1PSEN2 | |
| SCHEMBL6102944 | 0.89 | MAPK14 (0.47) | MAPK14CHEK1LRRK2FLT3PSEN1 | |
| SCHEMBL6100561 | 0.89 | MAPK14 (0.53) | MAPK14CHEK1LRRK2FLT3PSEN1 | |
| SCHEMBL6102940 | 0.89 | MAPK14 (0.47) | MAPK14CHEK1LRRK2FLT3PSEN1 | |
| SCHEMBL6100565 | 0.89 | MAPK14 (0.53) | MAPK14CHEK1LRRK2FLT3PSEN1 | |
| SCHEMBL6086556 | 0.87 | MAPK14 (0.46) | MAPK14CHEK1LRRK2FLT3PSEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490356-B1 | (3Z)-3-(3-HYDRO-ISOBENZOFURAN-1-YLIDENE)-1,3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS | ALLERGAN INC (US) | 2013-02-27 | — | — | EP | disclosed |
| US-7060844-B2 | (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. (US) | 2006-06-13 | — | — | US | disclosed |
| US-20060004084-A1 | (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2006-01-05 | — | — | US | disclosed |
| EP-1490356-A1 | (3Z)-3-(3-HYDRO-ISOBENZOFURAN-1-YLIDENE)-1,3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS | Allergan, Inc. (US) | 2004-12-29 | — | — | EP | disclosed |
| US-20040019098-A1 | (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2004-01-29 | — | — | US | disclosed |
| WO-2003084951-A1 | (3Z) -3-(3-HYDRO-ISOBENZOFURAN-1-YLIDENE)-1, 3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004084-A1 | (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | CDK2, ERBB2, MAP3K3 | MAPK14 186/4885CHEK1 322/4885LRRK2 545/4885 |
| US-20040019098-A1 | (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | CDK2, ERBB2, MAP3K3 | MAPK14 191/4885CHEK1 327/4885LRRK2 497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.